Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody.
Al-Khami AA, Youssef S, Abdiche Y, Nguyen H, Chou J, Kimberlin CR, Chin SM, Kamperschroer C, Jessen B, Kern B, Budimir N, Dillon CP, Xu A, Clark JD, Chou J, Kraynov E, Rajpal A, Lin JC, Salek-Ardakani S. Al-Khami AA, et al. Mol Cancer Ther. 2020 Oct;19(10):2105-2116. doi: 10.1158/1535-7163.MCT-20-0093. Epub 2020 Aug 26. Mol Cancer Ther. 2020. PMID: 32847983
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L, van Beek AA, de Ruiter V, Doukas M, Wei J, Fisher TS, Ching K, Yang W, van Loon K, Boor PPC, Rakké YS, Noordam L, Doornebosch P, Grünhagen D, Verhoef K, Polak WG, IJzermans JNM, Ni I, Yeung YA, Salek-Ardakani S, Sprengers D, Kwekkeboom J. Campos Carrascosa L, et al. J Immunother Cancer. 2020 Sep;8(2):e000816. doi: 10.1136/jitc-2020-000816. J Immunother Cancer. 2020. PMID: 32900860 Free PMC article.
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH, Dominik PK, Stanfield J, Ding S, Yang W, Kurd N, Llewellyn R, Heyen J, Wang C, Melton Z, Van Blarcom T, Lindquist KC, Chaparro-Riggers J, Salek-Ardakani S. Chen SH, et al. Among authors: salek ardakani s. J Immunother Cancer. 2021 Oct;9(10):e003464. doi: 10.1136/jitc-2021-003464. J Immunother Cancer. 2021. PMID: 34599020 Free PMC article.
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers.
Diab A, Hamid O, Thompson JA, Ros W, Eskens FALM, Doi T, Hu-Lieskovan S, Klempner SJ, Ganguly B, Fleener C, Wang X, Joh T, Liao K, Salek-Ardakani S, Taylor CT, Chou J, El-Khoueiry AB. Diab A, et al. Among authors: salek ardakani s. Clin Cancer Res. 2022 Jan 1;28(1):71-83. doi: 10.1158/1078-0432.CCR-21-0845. Epub 2021 Oct 6. Clin Cancer Res. 2022. PMID: 34615725 Free PMC article.
Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties.
Van Braeckel-Budimir N, Dolina JS, Wei J, Wang X, Chen SH, Santiago P, Tu G, Micci L, Al-Khami AA, Pfister S, Ram S, Sundar P, Thomas G, Long H, Yang W, Potluri S, Salek-Ardakani S. Van Braeckel-Budimir N, et al. Among authors: salek ardakani s. J Immunother Cancer. 2021 Dec;9(12):e003614. doi: 10.1136/jitc-2021-003614. J Immunother Cancer. 2021. PMID: 34903555 Free PMC article.
CD40 agonist-induced IL-12p40 potentiates hepatotoxicity.
Bonnans C, Thomas G, He W, Jung B, Chen W, Liao M, Heyen J, Buetow B, Pillai S, Matsumoto D, Chaparro-Riggers J, Salek-Ardakani S, Qu Y. Bonnans C, et al. J Immunother Cancer. 2020 May;8(1):e000624. doi: 10.1136/jitc-2020-000624. J Immunother Cancer. 2020. PMID: 32474414 Free PMC article.
83 results